Gyre Therapeutics, Inc. Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31)
Gyre Therapeutics, Inc. (GYRE) had Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) of $298.00 thousand as of 2013-03-31, per its 10-Q filed 2013-05-08.
Discontinued › Notes › Investments
us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain · last filed 2013-05-08
- 2013-03-31: Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) $298.00K.
- 2012-12-31: Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) $317.00K.
- 2012-09-30: Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) $378.00K.
- 2012-06-30: Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) $225.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) |
|---|---|
| 2013-03-31 | $298.00K 10-Q · filed 2013-05-08 |
| 2012-12-31 | $317.00K 10-Q · filed 2013-05-08 |
| 2012-09-30 | $378.00K 10-Q · filed 2012-11-08 |
| 2012-06-30 | $225.00K 10-Q · filed 2012-08-09 |
| 2011-12-31 | $183.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |